Atrium Therapeutics launched as a spinout carrying Avidity Biosciences’ preclinical precision‑cardiology programs and closed with approximately $270 million in cash. The company’s two lead candidates, ATR‑1072 (PRKAG2 syndrome) and ATR‑1086 (PLN cardiomyopathy), use antibody‑oligonucleotide conjugate (AOC) delivery to target RNA in cardiac tissue. Atrium plans an IND filing for ATR‑1072 in the second half of the year and a 2027 IND for ATR‑1086. The financing and platform continuity preserve cardiac‑targeted RNA delivery efforts separated from Novartis’ priorities and underscore demand for tissue‑selective oligonucleotide delivery in rare, life‑threatening cardiomyopathies.